Brian Gallagher
Partner @ SR One
Cambridge, United States
Brian Gallagher is a Series E investor at SR One in Cambridge focused on Therapeutics and Biotechnology. Brian Gallagher - Partner @ Abingworth
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Brian Gallagher invests in
Stages Brian Gallagher invests in
Countries Brian Gallagher invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Therapeutics 3 (33%)
- Biotechnology 3 (33%)
- Biopharma 2 (22%)
- Health Care 2 (22%)
- Medical 1 (11%)
Stage
- Series E 2 (22%)
- Series A 1 (11%)
- Series B 1 (11%)
- Series D 1 (11%)
- Series F 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $100M / Series F / Apr 09, 2018 | ||
| Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $33M / Series E / Oct 29, 2014 | ||
| Rein Therapeutics is a biopharmaceutical company that is developing therapies for pulmonary and fibrotic diseases. Its pipeline includes LTI-03 for idiopathic pulmonary fibrosis, LTI-01 for pleural effusion, and early programs for cystic fibrosis and systemic fibrosis using peptide and proenzyme approaches. | $33M / Series E / Oct 29, 2014 | ||
| Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $30M / Series E / Nov 18, 2013 | ||
| Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $12M / Series D / Jan 14, 2013 | ||
River Vision Development
|
River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York. | $17M / Series A / Dec 12, 2012 | |
| Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $15M / Series B / Jun 06, 2011 | ||
| Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene expression. | $22.3M / Series B / Jun 07, 2010 | ||
| Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. | $40M / Series D / Jun 11, 2009 |
Co-Investors
About SR One
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
SR One Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jill Carroll
Partner
|
|||
Simeon George
Chief Executive Officer
|
|||
Christopher Y. Chai
Venture Partner
|
|||
Iqbal Mufti
Partner
|
|||
Jens Eckstein
President
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Brian Gallagher invest in?
Brian Gallagher invests primarily in Therapeutics, Biotechnology and Biopharma startups, most often at Series E and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Brian Gallagher?
Public channels for Brian Gallagher include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Brian Gallagher last invest?
The most recent investment recorded for Brian Gallagher closed in Apr 2018. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
